Amneal Pharmaceuticals ( (AMRX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Amneal Pharmaceuticals shares moved after the company reported a strong fourth quarter and set 2026 guidance that points to a significant jump in EBITDA, driven by a pivot toward higher‑margin branded drugs and biosimilars. Following these results, Truist raised its price target on Amneal to $17 while reiterating its Buy rating, signaling continued confidence in the stock’s longer‑term prospects.
Investors are watching how this shift in Amneal’s product mix could support more stable and profitable growth in the coming years. The upgraded target suggests analysts see room for upside despite recent volatility in the share price, making the stock a closely watched name in the pharmaceutical space.
More about Amneal Pharmaceuticals
YTD Price Performance: 9.60%
Average Trading Volume: 2,512,515
Technical Sentiment Signal: Buy
Current Market Cap: $4.34B
For further insights into AMRX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.